| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Steele Clarke Smith, Mark S Wagne. Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro endocrinology letters. vol 35. issue 3. 2014-12-29. PMID:24977967. |
clinical endocannabinoid deficiency (cecd) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? |
2014-12-29 |
2023-08-13 |
Not clear |
| Steele Clarke Smith, Mark S Wagne. Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro endocrinology letters. vol 35. issue 3. 2014-12-29. PMID:24977967. |
ethan b. russo's paper of december 1, 2003 explored the concept of a clinical endocannabinoid deficiency (cecd) underlying the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome and other functional conditions alleviated by clinical cannabis. |
2014-12-29 |
2023-08-13 |
Not clear |
| S Grassin-Delyle, E Naline, A Buenestado, C Faisy, J-C Alvarez, H Salvator, C Abrial, C Advenier, L Zemoura, P Devillie. Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors. British journal of pharmacology. vol 171. issue 11. 2014-12-28. PMID:24467410. |
marijuana smoking is widespread in many countries, and the use of smoked synthetic cannabinoids is increasing. |
2014-12-28 |
2023-08-12 |
human |
| Jana Kucerova, Katarina Tabiova, Filippo Drago, Vincenzo Mical. Therapeutic potential of cannabinoids in schizophrenia. Recent patents on CNS drug discovery. vol 9. issue 1. 2014-12-22. PMID:24605939. |
the endocannabinoid system comprises of two g protein-coupled receptors (the cannabinoid receptors 1 and 2 [cb1 and cb2] for marijuana's psychoactive principle Δ(9)-tetrahydrocannabinol), their endogenous small lipid ligands (namely anandamide [aea] and 2-arachidonoylglycerol [2-ag], also known as endocannabinoids), and proteins for endocannabinoid biosynthesis and degradation. |
2014-12-22 |
2023-08-12 |
Not clear |
| M Takematsu, R S Hoffman, L S Nelson, J M Schechter, J H Moran, S W Wiene. A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clinical toxicology (Philadelphia, Pa.). vol 52. issue 9. 2014-12-22. PMID:25241766. |
synthetic cannabinoids are increasingly used in the united states as marijuana substitutes. |
2014-12-22 |
2023-08-13 |
Not clear |
| Raphael Mechoulam, Lumír O Hanuš, Roger Pertwee, Allyn C Howlet. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nature reviews. Neuroscience. vol 15. issue 11. 2014-12-17. PMID:25315390. |
isolation and structure elucidation of most of the major cannabinoid constituents--including Δ(9)-tetrahydrocannabinol (Δ(9)-thc), which is the principal psychoactive molecule in cannabis sativa--was achieved in the 1960s and 1970s. |
2014-12-17 |
2023-08-13 |
Not clear |
| Jae Myung Cha, Richard A Kozarek, Otto S Li. Case of cannabinoid hyperemesis syndrome with long-term follow-up. World journal of clinical cases. vol 2. issue 12. 2014-12-17. PMID:25516874. |
long-term cannabis use may be associated with attacks of severe nausea and vomiting, and a characteristic learned behavior of compulsive hot bathing, termed cannabinoid hyperemesis syndrome (chs). |
2014-12-17 |
2023-08-13 |
Not clear |
| M Zubrzycki, A Liebold, A Janecka, M Zubrzyck. A new face of endocannabinoids in pharmacotherapy. Part I: protective role of endocannabinoids in hypertension and myocardial infarction. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. vol 65. issue 2. 2014-12-16. PMID:24781727. |
cannabinoids are compounds which were first isolated from the cannabis sativa plant. |
2014-12-16 |
2023-08-13 |
Not clear |
| Matthijs G Bossong, J Martijn Jansma, Sagnik Bhattacharyya, Nick F Ramse. Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (THC). Progress in neuro-psychopharmacology & biological psychiatry. vol 52. 2014-12-12. PMID:24380726. |
role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (thc). |
2014-12-12 |
2023-08-12 |
human |
| William S Hyatt, William E Fantegross. Δ9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice. Behavioural pharmacology. vol 25. issue 3. 2014-12-09. PMID:24625557. |
the emergence of high-efficacy synthetic cannabinoids as drugs of abuse in readily available k2/'spice' smoking blends has exposed users to much more potent and effective substances than the phytocannabinoids present in cannabis. |
2014-12-09 |
2023-08-12 |
mouse |
| Daniela Calvigioni, Yasmin L Hurd, Tibor Harkany, Erik Keimpem. Neuronal substrates and functional consequences of prenatal cannabis exposure. European child & adolescent psychiatry. vol 23. issue 10. 2014-12-05. PMID:24793873. |
in addition, potent herbal "legal" highs containing synthetic cannabinoids that mimic the effects of cannabis with unknown pharmacological and toxicological effects have gained rapid popularity amongst young adults. |
2014-12-05 |
2023-08-13 |
Not clear |
| Sheeja Navakkode, Martin Kort. Pharmacological activation of CB1 receptor modulates long term potentiation by interfering with protein synthesis. Neuropharmacology. vol 79. 2014-12-03. PMID:24412673. |
cognitive impairment is one of the most important side effects associated with cannabis drug abuse, as well as the serious issue concerning the therapeutic use of cannabinoids. |
2014-12-03 |
2023-08-12 |
Not clear |
| Murat Oz, Lina Al Kury, Susan Yang Keun-Hang, Mohamed Mahgoub, Sehamuddin Galadar. Cellular approaches to the interaction between cannabinoid receptor ligands and nicotinic acetylcholine receptors. European journal of pharmacology. vol 731. 2014-12-03. PMID:24642359. |
cannabis plant contains various phytochemicals that bind to cannabinoid receptors. |
2014-12-03 |
2023-08-12 |
Not clear |
| Justine Renard, Marie-Odile Krebs, Gwenaëlle Le Pen, Thérèse M Ja. Long-term consequences of adolescent cannabinoid exposure in adult psychopathology. Frontiers in neuroscience. vol 8. 2014-11-26. PMID:25426017. |
delta-9-tetrahydrocanabinol (thc), the principal psychoactive component in marijuana, acts as a partial agonist of the cannabinoid type 1 receptor (cb1r). |
2014-11-26 |
2023-08-13 |
human |
| M V Fogaça, F M C V Reis, A C Campos, F S Guimarãe. Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 3. 2014-11-25. PMID:24321837. |
in a previous study, intra-pl injection of cannabidiol (cbd), a major non-psychotomimetic cannabinoid present in the cannabis sativa plant, reduced the expression of fear conditioning response. |
2014-11-25 |
2023-08-12 |
Not clear |
| Anusha Penumarti, Abdel A Abdel-Rahma. Neuronal nitric oxide synthase-dependent elevation in adiponectin in the rostral ventrolateral medulla underlies g protein-coupled receptor 18-mediated hypotension in conscious rats. The Journal of pharmacology and experimental therapeutics. vol 351. issue 1. 2014-11-25. PMID:25100751. |
direct activation of the endocannabinoid receptor g protein-coupled receptor 18 (gpr18) in the rostral ventrolateral medulla (rvlm) of conscious rats by abnormal cannabidiol (abn cbd; trans-4-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) elevates local nitric oxide (no) and adiponectin (adn) levels and reduces oxidative stress and blood pressure (bp). |
2014-11-25 |
2023-08-13 |
rat |
| Ruud van Winkel, Rebecca Kueppe. Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis. Annual review of clinical psychology. vol 10. 2014-11-18. PMID:24471373. |
in order to understand how cannabis use may lead to an increased risk for psychosis, in the present article we (a) review the epidemiological, neurobiological, and genetic evidence linking cannabinoids and psychosis, (b) assess the quality of the evidence, and finally (c) try to integrate the most robust findings into a neurodevelopmental model of cannabis-induced psychosis and identify the gaps in knowledge that are in need of further investigation. |
2014-11-18 |
2023-08-12 |
Not clear |
| Donna M Lis. Designer drugs. Patients may be using synthetic cannabinoids more than you think. JEMS : a journal of emergency medical services. vol 39. issue 9. 2014-11-13. PMID:25322519. |
they produce marijuana-like effects from binding to cannabinoid receptors in the central nervous system (cns) and have sometimes been referred to as "fake pot," "legal weed," "new marijuana" and "legal high." |
2014-11-13 |
2023-08-13 |
Not clear |
| Andrew J Hill, Nicholas A Jones, Imogen Smith, Charlotte L Hill, Claire M Williams, Gary J Stephens, Benjamin J Whalle. Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se. Neuroscience letters. vol 566. 2014-11-11. PMID:24642454. |
cannabidiol (cbd) is a non-psychoactive, well-tolerated, anticonvulsant plant cannabinoid, although its mechanism(s) of seizure suppression remains unknown. |
2014-11-11 |
2023-08-12 |
mouse |
| Scott V Masten, Gloriam Vanine Guenzburge. Changes in driver cannabinoid prevalence in 12 U.S. states after implementing medical marijuana laws. Journal of safety research. vol 50. 2014-11-03. PMID:25142359. |
changes in driver cannabinoid prevalence in 12 u.s. states after implementing medical marijuana laws. |
2014-11-03 |
2023-08-13 |
Not clear |